Literature DB >> 32078755

Atlas-based GABA mapping with 3D MEGA-MRSI: Cross-correlation to single-voxel MRS.

Ruoyun E Ma1,2,3, James B Murdoch4, Wolfgang Bogner5, Ovidiu Andronesi6, Ulrike Dydak2,3.   

Abstract

The purpose of this work is to develop and validate a new atlas-based metabolite quantification pipeline for edited magnetic resonance spectroscopic imaging (MEGA-MRSI) that enables group comparisons of brain structure-specific GABA levels. By using brain structure masks segmented from high-resolution MPRAGE images and coregistering these to MEGA-LASER 3D MRSI data, an automated regional quantification of neurochemical levels is demonstrated for the example of the thalamus. Thalamic gamma-aminobutyric acid + coedited macromolecules (GABA+) levels from 21 healthy subjects scanned at 3 T were cross-validated both against a single-voxel MEGA-PRESS acquisition in the same subjects and same scan sessions, as well as alternative MRSI processing techniques (ROI approach, four-voxel approach) using Pearson correlation analysis. In addition, reproducibility was compared across the MRSI processing techniques in test-retest data from 14 subjects. The atlas-based approach showed a significant correlation with SV MEGA-PRESS (correlation coefficient r [GABA+] = 0.63, P < 0.0001). However, the actual values for GABA+, NAA, tCr, GABA+/tCr and tNAA/tCr obtained from the atlas-based approach showed an offset to SV MEGA-PRESS levels, likely due to the fact that on average the thalamus mask used for the atlas-based approach only occupied 30% of the SVS volume, ie, somewhat different anatomies were sampled. Furthermore, the new atlas-based approach showed highly reproducible GABA+/tCr values with a low median coefficient of variance of 6.3%. In conclusion, the atlas-based metabolite quantification approach enables a more brain structure-specific comparison of GABA+ and other neurochemical levels across populations, even when using an MRSI technique with only cm-level resolution. This approach was successfully cross-validated against the typically used SVS technique as well as other different MRSI analysis methods, indicating the robustness of this quantification approach.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  GABA; MEGA-LASER; MEGA-PRESS; MRSI; validation

Mesh:

Substances:

Year:  2020        PMID: 32078755      PMCID: PMC7438238          DOI: 10.1002/nbm.4275

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  65 in total

1.  In vivo detection of gray and white matter differences in GABA concentration in the human brain.

Authors:  In-Young Choi; Sang-Pil Lee; Hellmut Merkle; Jun Shen
Journal:  Neuroimage       Date:  2006-08-01       Impact factor: 6.556

2.  31P RINEPT MRSI and VBM reveal alterations in brain aging associated with major depression.

Authors:  Sarah V Biedermann; Wolfgang Weber-Fahr; Traute Demirakca; Nuran Tunc-Skarka; Mareen Hoerst; Fritz Henn; Alexander Sartorius; Gabriele Ende
Journal:  Magn Reson Med       Date:  2014-05-05       Impact factor: 4.668

Review 3.  Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA.

Authors:  Paul G Mullins; David J McGonigle; Ruth L O'Gorman; Nicolaas A J Puts; Rishma Vidyasagar; C John Evans; Richard A E Edden
Journal:  Neuroimage       Date:  2012-12-13       Impact factor: 6.556

4.  Measuring the longitudinal relaxation time of GABA in vivo at 3 Tesla.

Authors:  Nicolaas A J Puts; Peter B Barker; Richard A E Edden
Journal:  J Magn Reson Imaging       Date:  2012-09-21       Impact factor: 4.813

5.  Spatial effects in the detection of gamma-aminobutyric acid: improved sensitivity at high fields using inner volume saturation.

Authors:  Richard A E Edden; Peter B Barker
Journal:  Magn Reson Med       Date:  2007-12       Impact factor: 4.668

Review 6.  Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies.

Authors:  Remmelt R Schür; Luc W R Draisma; Jannie P Wijnen; Marco P Boks; Martijn G J C Koevoets; Marian Joëls; Dennis W Klomp; René S Kahn; Christiaan H Vinkers
Journal:  Hum Brain Mapp       Date:  2016-05-04       Impact factor: 5.038

7.  The relationship between thalamic GABA content and resting cortical rhythm in neuropathic pain.

Authors:  Flavia Di Pietro; Paul M Macey; Caroline D Rae; Zeynab Alshelh; Vaughan G Macefield; E Russell Vickers; Luke A Henderson
Journal:  Hum Brain Mapp       Date:  2018-01-17       Impact factor: 5.038

8.  Discrimination between neurochemical and macromolecular signals in human frontal lobes using short echo time proton magnetic resonance spectroscopy.

Authors:  Mary A McLean; Robert J Simister; Gareth J Barker; John S Duncan
Journal:  Faraday Discuss       Date:  2004       Impact factor: 4.008

9.  Thalamic GABA predicts fine motor performance in manganese-exposed smelter workers.

Authors:  Zaiyang Long; Xiang-Rong Li; Jun Xu; Richard A E Edden; Wei-Ping Qin; Li-Ling Long; James B Murdoch; Wei Zheng; Yue-Ming Jiang; Ulrike Dydak
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

10.  GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study.

Authors:  Anouk Marsman; René C W Mandl; Dennis W J Klomp; Marc M Bohlken; Vincent O Boer; Anna Andreychenko; Wiepke Cahn; René S Kahn; Peter R Luijten; Hilleke E Hulshoff Pol
Journal:  Neuroimage Clin       Date:  2014-10-15       Impact factor: 4.881

View more
  2 in total

1.  ECLIPSE utilizing gradient-modulated offset-independent adiabaticity (GOIA) pulses for highly selective human brain proton MRSI.

Authors:  Chathura Kumaragamage; Henk M De Feyter; Peter Brown; Scott McIntyre; Terence W Nixon; Robin A de Graaf
Journal:  NMR Biomed       Date:  2020-10-01       Impact factor: 4.478

2.  Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder.

Authors:  Joshua T Kantrowitz; Zhengchao Dong; Matthew S Milak; Rain Rashid; Lawrence S Kegeles; Daniel C Javitt; Jeffrey A Lieberman; J John Mann
Journal:  Transl Psychiatry       Date:  2021-08-05       Impact factor: 6.222

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.